Table 2.
Circulating miRNAs in patients with BTC as potential diagnostic, prognostic, and predictive biomarkers.
| miRNA | Expression | Samples | N samples | Potential biomarker | Method | Clinical implication | Reference |
|---|---|---|---|---|---|---|---|
| hsa-miR-9 | ↑ | Bile | BTCs (9) HV (9) |
Diagnostic Prognostic |
RT-PCR | Metastasis | [61] |
|
| |||||||
| hsa-miR-145 | ↑ | Bile | BTCs (9) HV (9) |
Diagnostic | RT-PCR | — | [61] |
|
| |||||||
| hsa-miR-21 | ↑ | Plasma | BTCs (94) HV (50) BBD (2) |
Diagnostic | qRT-PCR | Inflammatory reaction | [62] |
| Peripheral blood | GBC (40) HV (40) |
Diagnostic | qRT-PCR | — | [47] | ||
|
| |||||||
| hsa-miR-150 | ↑ | Plasma | iCCA (15) | Diagnostic | qRT-PCR | Tumor progression | [63] |
|
| |||||||
| hsa-miR-106a | ↓ | Serum | CCA (103) | Prognostic | qRT-PCR | Lymph node metastasis | [64] |
| HV (20) | |||||||
|
| |||||||
| hsa-miR-126 | ↑ | Serum | PSC (40) CCA (31) HV (12) |
Diagnostic | RT-PCR | — | [65] |
|
| |||||||
| hsa-miR-26a | ↑ | Serum | PSC (40) CCA (31) HV (12) |
Diagnostic | RT-PCR | — | [65] |
|
| |||||||
| hsa-miR-30b | ↑ | Serum | PSC (40) CC (31) HV (12) |
Diagnostic | RT-PCR | — | [65] |
|
| |||||||
| hsa- miR-122 | ↑ | Serum | PSC (40) CC (31) HV (12) |
Diagnostic | RT-PCR | — | [65] |
|
| |||||||
| hsa-miR-1281 | ↑ | Serum | PSC (40) CC (31) HV (12) |
Diagnostic | RT-PCR | — | [65] |
|
| |||||||
| hsa-miR -187 | ↑ | Peripheral blood | GBC (40) HV (40) |
Diagnostic Prognostic Predictive |
qRT-PCR | Lymph node metastasis Poor prognosis |
[47] |
|
| |||||||
| hsa-miR-192 | ↑ | Peripheral blood | GBC (40) HV (40) |
Diagnostic Prognostic Predictive |
qRT-PCR | Inflammatory reaction Immune reaction Lymph node metastasis |
[47] |
| Serum | iCCA (11) HV (09) |
Diagnostic Prognostic |
miRNA RT-PCR array | Lymph node metastasis Poor prognosis |
[66] | ||
|
| |||||||
| hsa-miR-194 | ↑ | Serum | CCA (70) HV (70) |
Diagnostic | qRT-PCR | Tumor progression | [58] |
|
| |||||||
| hsa-miR -202 | ↑ | Peripheral blood | GBC (40) HV (40) |
Diagnostic Prognostic Predictive |
qRT-PCR | Lymph node metastasis | [47] |
|
| |||||||
| hsa-let- 7a | ↓ | Peripheral blood | GBC (40) HV (40) |
Diagnostic | qRT-PCR | — | [47] |
|
| |||||||
| hsa-miR -143 | ↓ | Peripheral blood | GBC (40) HV (40) |
Diagnostic Prognostic Predictive |
qRT-PCR | Inflammatory and immune reaction Lymph node metastasis |
[47] |
|
| |||||||
| hsa-miR-335 | ↓ | Peripheral blood | GBC (40) HV (40) |
Diagnostic | qRT-PCR | — | [47] |
|
| |||||||
| hsa-miR-1307-3p | ↓ | Plasma | iCCA (13) HV (5) |
Diagnostic | qRT-PCR | — | [67] |
|
| |||||||
| hsa-miR-1275 | ↑ | Plasma | iCCA (13) HV (5) |
Diagnostic | qRT-PCR | — | [67] |
|
| |||||||
| hsa- miR-320b | ↑ | Plasma | iCCA (13) HVs (5) |
Diagnostic | qRT-PCR | — | [67] |
|
| |||||||
| hsa-miR-874 | ↑ | Plasma | iCCA (13) HVs (5) |
Diagnostic | qRT-PCR | — | [67] |
|
| |||||||
| hsa-miR-483-5p | ↑ | Plasma | iCCA (13) HV (5) |
Diagnostic | qRT-PCR | — | [67] |
| Serum | CCA (70) HV (70) |
Diagnostic | qRT-PCR | Tumor progression | [58] | ||
|
| |||||||
| hsa-miR-885-5p | ↑ | Plasma | iCCA (13) HV (5) |
Diagnostic | qRT-PCR | — | [67] |
|
| |||||||
| hsa-miR-92b-3p | ↑ | Plasma | iCCA (13) HV (5) |
Diagnostic | qRT-PCR | — | [67] |
|
| |||||||
| hsa-miR-505-3p | ↑ | Plasma | iCCA (13) HV (5) |
Diagnostic | qRT-PCR | — | [67] |
|
| |||||||
| hsa-miR-6836-3p | ↑ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
|
| |||||||
| hsa-miR-6075 | ↑ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
|
| |||||||
| hsa- miR-4634 | ↑ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
|
| |||||||
| hsa-miR-4294 | ↓ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
|
| |||||||
| hsa-miR-6880-5p | ↓ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
|
| |||||||
| hsa-miR-6799-5p | ↓ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
|
| |||||||
| hsa-miR-125a-3p, | ↓ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | Tumor progression | [68] |
|
| |||||||
| hsa-miR-4530 | ↓ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
|
| |||||||
| hsa-miR-7114-5p | ↓ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
|
| |||||||
| hsa-miR-4476 | ↓ | Serum | BTCs (98) HV (150) |
Diagnostic | 3D-Gene | — | [68] |
BBD: benign biliary disorders; BTCs: biliary tract cancers; CCA: cholangiocarcinoma; iCCA: intrahepatic cholangiocarcinoma; GBC: gallbladder cancer; HV: heath volunteers; PSC: primary sclerosing cholangitis.